Drug Trial Radar · NCT04893811
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Aug 18, 2021
Primary completion
Sep 6, 2023
Study completion Sep 6, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic and complement-deficient individuals ≥10 years of age.
Conditions
- Meningococcal Vaccine
Interventions
TrumenbaBiological
Bivalent recombinant lipoprotein 2086 vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at BaselineTime frame: Baseline (Before Vaccination 1 on Day 1/Month 0)
- Percentage of Participants With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2Time frame: 1 Month after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 1Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 2Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 1Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 2Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting AEs During 30 Days After Vaccination 2Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting AEs During 30 Days After Any VaccinationTime frame: 30 Days after any Vaccination
- Percentage of Participants Reporting AEs During the Vaccination PhaseTime frame: Vaccination Phase: From Vaccination 1 through one Month after Vaccination 2 (approximately 7 Months)
- Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting SAEs During 30 Days After Vaccination 2Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting SAEs During 30 Days After Any VaccinationTime frame: 30 Days after any Vaccination
- Percentage of Participants Reporting SAEs During the Vaccination PhaseTime frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
- Percentage of Participants Reporting SAEs During the Follow-up PhaseTime frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
- Percentage of Participants Reporting SAEs During the Entire StudyTime frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
- Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting MAEs During 30 Days After Vaccination 2Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants Reporting MAEs During 30 Days After Any VaccinationTime frame: 30 Days after any Vaccination
- Percentage of Participants Reporting MAEs During the Vaccination PhaseTime frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
- Percentage of Participants Reporting MAEs During the Follow-up PhaseTime frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
- Percentage of Participants Reporting MAEs During the Entire StudyTime frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
- Percentage of Participants Reporting Immediate AEs After Vaccination 1Time frame: 30 Minutes post Vaccination 1 (Vaccination 1 on Day 1/Month 0)
- Percentage of Participants Reporting Immediate AEs After Vaccination 2Time frame: 30 Minutes post Vaccination 2 (Vaccination 2 at Month 6)
- Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination PhaseTime frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
- Percentage of Participants With NDCMC During the Follow-up PhaseTime frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
- Percentage of Participants With NDCMC During the Entire StudyTime frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
- Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination PhaseTime frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3
Brno, Czechia
Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3
Brno, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
IN-VIVO Sp. z o.o.
Bydgoszcz, Poland
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
Krakow, Poland
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland
Szpital Bielański im. Ks. Jerzego Popiełuszki SPZOZ
Warsaw, Poland
Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
Adana, Turkey (Türkiye)
Acibadem Adana Hastanesi
Adana, Turkey (Türkiye)
Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
Adana, Turkey (Türkiye)
Hacettepe Universitesi Tip Fakultesi
Ankara, Turkey (Türkiye)
Mersin Universitesi Tip Fakultesi Hastanesi
Mersin, Turkey (Türkiye)
Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
Adana, Yüreği̇r, Turkey (Türkiye)
Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
Adana, Yüreği̇r, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.